Journal of the Korean Ophthalmological Society 2004;45(10):1674-1680.
Published online October 1, 2004.
Interferon-alpha in the Treatment of Behcet's Disease.
Hyung Gil Ko, Jung Won Han, Min Ho Kim, Won Gi Lee
1Department of Ophthalmology, Uijongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #65-1 Kumo-dong, Uijongbu city, Kyunggi-do, Korea. saint@catholic.ac.kr
2Apgujung St. Mary's Eye Center, Korea.
베세트병에 대한 알파인터페론의 치료효과
고형길 ( Hyung Gil Ko ) , 한정원 ( Jung Won Han ) , 김민호 ( Min Ho Kim ) , 이원기 ( Won Gi Lee )
Abstract
PURPOSE
To determine the therapeutic efficacy of interferon-alpha on patients with Behcet's disease who have been resistant to conventional therapies. METHODS: We treated 22 eyes of 13 patients with interferon-alpha for a mean of 20.5 months. They were given 3 million units interferon-alpha subcutaneously three times a week. Using slit lamp microscopy, fluorescent angiography, the authors compared visual acuity, frequency of relapse of uveitis and complications of interferon-alpha. RESULTS: The average ocular attack rate fell from 0.41 times a month to 0.19 times after interferon therapy. In addition, the degree of intraocular inflammation and especially retinal vasculitis decreased. There were no side effects significant enough to stop using interferon. CONCLUSIONS: Therapy with interferon-alpha seems to be an effective and safe regimen in Behcet's disease for refractory ocular attack and for the protection of vision.
Key Words: Behcet's disease;Interferon-alpha


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Jeokseon Hyundai BD
130, Sajik-ro, Jongno-gu, Seoul 03170, Korea
Tel: +82-2-2271-6603    Fax: +82-2-2277-5194    E-mail: kos@ijpnc.com                

Copyright © 2026 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next